Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

Table 2 Percentage of patients who responded in terms of rapid virologic response, early virologic response, end of the treatment virologic response, and sustained virologic response in genotypes 1, 3 and 4 by intention-to-treat analysis

Parameter	Genotype 1	Genotype 31	Genotype 4
	(n = 27)	(n = 56)	(n = 17)
RVR	25.9%	71.4%	58.8%
EVR	74.1%	87.5%	88.2%
ETVR	59.2%	78.6%	70.5%
SVR	44.4%	64.3%	52.9%

¹Includes one patient with genotype 2. RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response; ETVR: End of treatment virologic response.